The unfolded protein response, or UPR, is the ER’s emergency broadcast system. The ER is the cellular factory where secreted and membrane proteins are folded, modified, and checked for quality before being shipped onward. When misfolded proteins or overloaded folding capacity threaten to clog the works, sensors embedded in the ER membrane switch on a transcriptional program that expands the organelle’s folding capacity and, if the crisis is unresolved, pushes the cell toward self-destruction. In humans, chronic activation of this pathway is implicated in neurodegeneration, diabetes, and cancer, making the wiring of the alarm circuit a matter of intense biomedical interest.

Researchers led by Liying Guan, Tong Zhang, Zhigao Zhan, Yingchun Wang, Xun Huang, and Mei Ding approached the question from an unusual angle: they deliberately overloaded neurons in the transparent roundworm Caenorhabditis elegans with a single membrane protein and watched what happened. Their cargo of choice was UNC-9, a gap junction protein of the innexin family that normally forms intercellular channels between cells. When UNC-9 is overproduced in neurons, it floods the ER with more membrane cargo than the organelle can comfortably fold and process, and the team found that this overload cell-autonomously switches on the IRE-1–XBP-1 branch of the UPR—the most ancient and conserved of the pathway’s three sensor arms.

That result alone was expected; flooding a compartment with membrane protein is a classic way to provoke ER stress. The real revelation came when the team started removing pieces of the transport machinery. Two proteins called ERGI-2 and ERGI-3, which operate in the early secretory pathway that carries newly made cargo from the ER to the Golgi, turned out to be essential for the alarm. When the researchers disrupted either ERGI-2 or ERGI-3, the IRE-1–XBP-1 response to excess UNC-9 was sharply blunted. The overloaded cargo protein also lost its proper localization within the cell, drifting away from its normal compartments.

For decades, ER-to-Golgi trafficking components have been studied primarily as couriers: they package cargo into vesicles, bud them off the ER, and deliver them to the Golgi for further processing. The new findings suggest these proteins have a second, unappreciated job description. Rather than merely carrying proteins, ERGI-2 and ERGI-3 appear to monitor the load they are carrying and communicate that load to the stress sensors. Disrupting them does not simply slow down shipping—it silences a signaling channel between the trafficking apparatus and the UPR machinery.

The molecular evidence for this coupling is striking. Using biochemical assays, the researchers showed that ERGI-2 and ERGI-3 physically interact with both UNC-9, the excess cargo, and HSP-4, the worm equivalent of BiP, the master ER chaperone that also serves as the intracellular leash holding the IRE-1 sensor in its inactive state. This triple interaction places the trafficking proteins at the exact junction where cargo handling meets stress sensing, suggesting a model in which they help hand overloaded cargo to the chaperone–sensor system, effectively translating a traffic jam into a biochemical signal.

Equally important is what the team found when they changed the cargo. The requirement for ERGI-2 and ERGI-3 is not a general feature of ER stress; it is cargo-selective. Overexpressing UNC-7, a close relative of UNC-9 from the same innexin family, still triggers the UPR in worms lacking functional ERGI-2 or ERGI-3, as does overexpression of unrelated proteins. In other words, the basic alarm system works perfectly well without these trafficking proteins for many kinds of stress. It is specifically the handling of excessive UNC-9 that depends on them, implying that different cargos engage different routes to the same stress sensor—a level of specificity that few models of the UPR anticipated.

The relationship also runs in the opposite direction. When the researchers activated the IRE-1–XBP-1 pathway in ergi-2 or ergi-3 mutants, they observed a reduction in the abnormal accumulation of UNC-9 that characterizes those mutants. This feedback suggests that the UPR is not just a downstream consequence of trafficking problems but an active participant in managing them: switching on the stress response helps clear or prevent the aberrant buildup of cargo that clogs the system when the transport machinery is impaired.

Because C. elegans is a genetically tractable animal with nervous system organization that echoes principles found across the animal kingdom, the findings carry weight well beyond the worm. The early secretory pathway and the IRE-1–XBP-1 arm of the UPR are conserved from yeast to humans, and mammalian cells contain proteins related to ERGI-2 and ERGI-3. If the cargo-selective coupling observed in worm neurons holds in other systems, it could explain a long-standing puzzle: why some diseases of protein overproduction—certain neurodegenerative conditions driven by accumulation of specific membrane proteins, for example—unfold the way they do, and why the stress response sometimes fails to engage even when the ER is visibly overwhelmed.

The study also reframes how scientists think about the secretory pathway as a whole. Rather than a passive pipeline that simply moves proteins from point A to point B, the ER-to-Golgi system emerges as an integrated sensor network in which individual trafficking components act as gatekeepers for particular cargos, deciding not only whether a protein gets shipped but whether the cell should know about the strain it is under. As the authors conclude, ER-to-Golgi trafficking proteins function as cargo-selective regulators that link secretory-pathway demand to adaptive UPR signaling—a conclusion that transforms a humble group of transport factors into active participants in the cell’s decision to fight or fold. For researchers hunting the roots of proteostasis diseases, the message is clear: to understand how cells sense stress, follow the trucks, not just the alarms.

Subject of Research: Cargo-selective regulation of the unfolded protein response by ER-to-Golgi trafficking proteins in C. elegans neurons

Article Title: ER-to-Golgi transport machinery promotes the excessive cargo-triggered unfolded protein response in C . elegans

Article References: Guan, L., Zhang, T., Zhan, Z., Wang, Y., Huang, X., & Ding, M. (2026). ER-to-Golgi transport machinery promotes the excessive cargo-triggered unfolded protein response in C. elegans. PLOS Genetics, 22(9), e1012301. https://doi.org/10.1371/journal.pgen.1012301

Image Credits: AI Generated

DOI: 10.1371/journal.pgen.1012301

Keywords: unfolded protein response, ER stress, ER-to-Golgi transport, C. elegans, IRE-1, XBP-1, UNC-9, innexin, secretory pathway, BiP, proteostasis, neurobiology

The unfolded protein response, or UPR, exists because the endoplasmic reticulum is the cell’s protein-folding factory. When oncogenic stress, oxidative damage or metabolic strain disrupts folding, misfolded proteins pile up in the ER lumen, a condition known as ER stress. Three transmembrane sensors then sound the alarm: IRE1α, PERK and ATF6. IRE1α, a dual kinase and ribonuclease, splices the mRNA of X-box binding protein 1 to produce the transcription factor XBP1s, which ramps up production of chaperones and folding enzymes, while also degrading selected mRNAs through a process called regulated IRE1-dependent decay. PERK phosphorylates the translation initiation factor eIF2α, throttling global protein synthesis to lighten the folding load while permitting translation of ATF4, which steers the cell toward redox balance and metabolic adaptation. ATF6 travels to the Golgi apparatus, where it is cleaved into a cytosolic transcription factor that boosts folding capacity. Together these branches either restore order or, if the damage is beyond repair, push the cell into apoptosis.

What makes the UPR so consequential for cancer immunology is that the same secretory pathway it governs is the one tumours and immune cells use to talk to each other. Death receptors, immune checkpoint ligands such as PD-L1, chemokines and cytokines all depend on ER function for their production and trafficking. The review lays out three arenas in which tumour-intrinsic UPR signalling shapes the immune battlefield: immune recognition of tumour cells, immune-mediated tumour cell killing, and the broader chemical and vesicular communication between tumour and immune cells. In each arena, the evidence points to a system that can be bent toward immune evasion.

Immune recognition begins with antigen presentation. Tumour-derived mutant proteins are chopped by the proteasome into peptides, ferried into the ER by the transporter associated with antigen processing, loaded onto MHC class I molecules with the help of chaperones such as Tapasin, and displayed on the cell surface for scrutiny by CD8-positive cytotoxic T cells. NK cells, by contrast, monitor MHC-I expression itself, becoming activated when it drops or when stress ligands appear. The review details how UPR signalling can sabotage this display at multiple points. In lung and cervical cancer cells, ER stress raises XBP1s, which induces the microRNA miR-346; this microRNA targets TAP1 mRNA and cuts off the peptide supply to the ER. XBP1 inhibition restores surface MHC-I in tongue squamous cell carcinoma by suppressing TPP2, a protease that devours antigenic peptides. IRE1-dependent decay can even degrade the mRNAs encoding MHC-I heavy chains and Tapasin in dendritic cells, limiting T cell activation from the other side of the synapse. PERK contributes too: by attenuating translation through eIF2α phosphorylation, it reduces the pool of peptides available for loading onto MHC-I molecules.

A second recognition route is immunogenic cell death, a form of dying that broadcasts danger signals. When chemotherapy or radiation triggers ER stress, the chaperone calreticulin flips to the cell surface as an ‘eat me’ signal for dendritic cells via the receptor LRP1, while ATP and HMGB1 spill out of the dying cell to activate immune receptors such as P2X7R and TLR4. Here the UPR can work in the immune system’s favour. PERK-eIF2α signalling has emerged as a major driver of calreticulin exposure, apparently through caspase-8-dependent trafficking of the chaperone from the ER to the plasma membrane via the Golgi. In murine melanoma, doxorubicin-induced ER stress promotes calreticulin exposure, and its engagement of the activating receptor NKp46 strengthens the drug’s anti-tumour effect. Intriguingly, the review notes that ICD can also occur when PERK is inhibited in ER-stressed melanoma cells, with dying cells exposing calreticulin and releasing HMGB1 and ATP independently of caspase activation — a reminder that PERK is important but not universally required, and that the rules depend on the type of stress and the tumour involved. Blocking the ER chaperone BiP, which normally holds the three UPR sensors in check, similarly enhances radiation-induced ICD in human glioma stem cells.

Once a tumour cell is recognised, it must still be killed, and here the UPR again tilts the scales. PD-L1, the co-inhibitory ligand that engages PD-1 on T cells and drives their exhaustion, is upregulated by ER stressors such as thapsigargin or the BiP inhibitor HA15 through IRE1α’s RNase activity, and BiP appears to stabilise PD-L1 protein directly in triple-negative breast, head and neck and pancreatic cancer cell lines. Strikingly, combining HA15 with anti-PD-1 therapy boosts CD8-positive T cell infiltration and cytotoxicity in murine melanoma, showing that UPR-driven checkpoint modulation can be therapeutically exploited. NK cell attack is blunted through a parallel route: IRE1α-XBP1s signalling represses the stress ligand MICA in melanoma cells by inhibiting the transcription factor E2F1, while ER stress lowers MICA/B post-transcriptionally in hepatocellular carcinoma, and PERK-eIF2α-ATF4 signalling regulates additional NK-activating ligands including ULBP1 and B7-H6. Even the extrinsic death receptor pathway is under UPR control, with XBP1s promoting CD95 expression while RIDD suppresses it, and PERK knockdown independently altering CD95 protein levels.

Beyond direct contact, tumour cells flood their surroundings with soluble signals and extracellular vesicles, and the UPR shapes both. ER stress in prostate cancer, melanoma and lung carcinoma cells promotes release of IL-6, IL-23 and TNF-α, which polarise macrophages toward a pro-inflammatory phenotype via TLR4 while simultaneously impairing dendritic cell cross-presentation and CD8-positive T cell activation. By contrast, HA15-induced ER stress in melanoma enhances secretion of the chemokines CXCL9-11 along with IL-6 and TNF-α, drawing cytotoxic T cells into the tumour — an example of the UPR’s double-edged nature. In triple-negative breast cancer and glioblastoma, IRE1α activity remodels the secretome and myeloid cell recruitment, while loss of tumour IRE1α in lung cancer increases dendritic cell infiltration partly by reducing the immunosuppressive lipid prostaglandin E2. Exosomes add another layer: PERK and IRE1α regulate multivesicular body formation, ATF4 limits lysosomal acidification by inhibiting vesicular-ATPase assembly, and ER stress boosts release of exosomes carrying PD-L1 or miR-27a-3p, which push macrophages toward pro-tumourigenic, PD-L1-high states.

The immune cells themselves are not passive bystanders. Tumour-derived factors activate PERK-ATF4 signalling in macrophages within glioblastoma, driving GLUT1 expression, glucose uptake and lactate production that support an immunosuppressive phenotype; in melanoma, the same pathway promotes serine biosynthesis and lipid oxidation through ATF4-PSAT1. PERK also governs myeloid-derived suppressor cell function through NRF2, and its loss triggers mitochondrial dysfunction and STING-dependent immune activation that reinvigorates CD8-positive T cell responses. Pharmacologically, the IRE1α kinase inhibitor Compound 18 reduced tumour-associated fibroblasts and myeloid-derived suppressor cells in breast tumour xenografts, while the RNase inhibitor MKC8866 — now in Phase 2 clinical trials as ORIN1001 — synergised with docetaxel and with anti-PD-1 therapy to increase T cell and NK infiltration in mouse models. PERK deletion in melanoma cells shrank tumours only in mice with functional T cells, underscoring the immune dependence of the effect, and the PERK inhibitor HC-5404 is being evaluated in a Phase 1 trial across multiple solid tumours.

The review’s central message is that UPR signalling is neither friend nor foe to anti-tumour immunity but a context-dependent dial. Acute ER stress can render tumours more immunogenic and vulnerable, whereas chronic stress fosters adaptation and immune suppression, with the outcome shaped by which branch is engaged, the intensity and duration of stress, tumour lineage and the surrounding immune landscape. The authors highlight the tantalising possibility that IRE1α inhibition can convert immunologically cold tumours into hot ones, restoring sensitivity to checkpoint inhibitors, as seen when docetaxel and MKC8866 were combined in triple-negative breast cancer models. Yet because the UPR is essential for the survival and function of secretory immune cells, the therapeutic window may be narrow, demanding careful target selection, dosing and combination strategies. Open questions abound — whether UPR modulation can enhance CAR-T and CAR-NK cell therapies, and which tumour types with high basal UPR activity stand to benefit most — but the answer to the last may already be taking shape: tumours with pre-existing immune infiltration, where the conversation between cancer and immunity is still alive enough to be redirected.

Subject of Research: The role of the unfolded protein response in regulating tumour-immune cell communication in the tumour microenvironment

Article Title: The Unfolded Protein Response as a Modulator of Cancer‐Immune Cell Communication in the Tumour Microenvironment

Article References: Chee, Y. H., Moncan, M., Reidy, E., Gorman, A. M., & Samali, A. (2026). The Unfolded Protein Response as a Modulator of Cancer‐Immune Cell Communication in the Tumour Microenvironment. Journal of Cellular and Molecular Medicine, 30(19), Article e71380. https://doi.org/10.1111/jcmm.71380

Image Credits: AI Generated

DOI: 10.1111/jcmm.71380

Keywords: unfolded protein response, ER stress, tumour microenvironment, cancer immunotherapy, IRE1α, PERK, PD-L1, antigen presentation, immunogenic cell death, NK cells, T cells, exosomes

The stakes could hardly be higher. According to the review, led by Olabisi Tajudeen Obafemi of the University of South Africa and colleagues, the global number of people living with diabetes surged from 200 million in 1990 to 830 million in 2022. Type 2 diabetes accounts for roughly 90 to 95 percent of those cases and is defined by insulin resistance paired with an insufficient compensatory surge of insulin. Persistent high blood glucose progressively damages the vascular, renal, neurological, ocular and cardiovascular systems, generating enormous morbidity and healthcare expenditure. Current drugs, including sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, mostly manage glucose downstream of the underlying cellular damage.

The authors contend that upstream stress-response pathways deserve far more therapeutic attention because they lie closer to the molecular origins of the disease. Among these, the IRE1α/XBP1 arm of the UPR is the most evolutionarily conserved, meaning that findings in model organisms often translate more readily to human biology. IRE1α is a transmembrane protein with a stress-sensing domain inside the ER lumen and kinase plus endoribonuclease (RNase) domains facing the cytoplasm. Under resting conditions, the chaperone GRP78, also known as BiP, keeps IRE1α inactive. When misfolded proteins accumulate, GRP78 detaches to handle them, allowing IRE1α to oligomerize and trans-autophosphorylate, thereby switching on its RNase domain.

That RNase activity performs one of the most remarkable feats in molecular biology: the unconventional splicing of X-box binding protein 1 (XBP1) mRNA. IRE1α excises a 26-nucleotide intron from XBP1 mRNA in the cytoplasm, producing a frameshift that generates the spliced transcription factor XBP1s. Once in the nucleus, XBP1s switches on genes for ER-associated protein folding, quality control, ER expansion, lipid biosynthesis and enhanced secretory capacity. In its adaptive mode, the pathway is a lifeline, expanding the cell’s folding factory to meet demand. But when ER stress becomes chronic, the same machinery turns destructive, engaging regulated IRE1-dependent decay (RIDD), which degrades essential transcripts, and recruiting inflammatory stress kinases.

The review details how this dual personality plays out across metabolically active tissues. In the liver, XBP1s suppresses gluconeogenesis by promoting the degradation of the transcription factor FOXO1, improving glucose tolerance, while fasting signals phosphorylate hepatic IRE1α at serine 724 to enhance gluconeogenic genes independently of XBP1s. In adipose tissue, XBP1s maintains adipocyte differentiation through the C/EBP family of transcription factors. In pancreatic beta cells, glucose-induced XBP1 splicing expands the machinery needed for proinsulin folding and secretion while limiting oxidative stress; beta-cell-specific XBP1 deficiency reduces insulin granules and weakens glucose-stimulated insulin secretion. Even skeletal muscle uses the pathway adaptively after injury to support regeneration.

Trouble begins when glucotoxicity and lipotoxicity sustain IRE1α signaling beyond its adaptive window. Chronic hyperglycemia hyperactivates IRE1α in beta cells, suppressing insulin gene expression and degrading insulin mRNA through RIDD, converting a protective response into secretory failure. Meanwhile, IRE1α recruits the adaptor protein TRAF2 and activates c-Jun N-terminal kinase (JNK), which phosphorylates insulin receptor substrate-1 on inhibitory serine residues. This blocks downstream PI3K/AKT signaling, reduces GLUT4-mediated glucose uptake and drives systemic insulin resistance. In skeletal muscle, XBP1 and ATF6 upregulate the phosphatase SKIP, further attenuating insulin-stimulated glucose uptake. The result is a feed-forward loop: excess nutrients fuel ER stress, stress kinases blunt insulin action, insulin resistance increases beta-cell workload, and the extra biosynthetic burden deepens ER stress.

The inflammatory consequences may be the most striking. The review describes how hyperactivated IRE1α lowers levels of microRNA-17, which normally represses thioredoxin-interacting protein (TXNIP). Stabilized TXNIP mRNA then promotes activation of the NLRP3 inflammasome, triggering caspase-1-mediated maturation of the inflammatory cytokines IL-1β and IL-18. IRE1α/TRAF2 signaling also activates NF-κB, elevating TNF-α, IL-6 and IL-1β and sustaining the low-grade metabolic inflammation that characterizes obesity and T2DM. The pathway even intersects oxidative stress signaling: acute oxidative stress induces IRE1α sulfenylation and activates an IRE1α–p38–NRF2 antioxidant axis, while in diabetic nephropathy a persistent XBP1–HRD1 axis ubiquitinates NRF2 and strips away renal antioxidant protection.

What elevates the review beyond mechanism is its synthesis of preclinical pharmacology on both sides of the pathway. On the activation side, the small molecule IXA4 selectively boosted adaptive IRE1/XBP1s signaling in diet-induced obese mice, reprogramming the hepatic transcriptome to reduce glucose production and steatosis without triggering RIDD. A successor compound, IXA62, extended activity to kidney and lung and increased glucose-stimulated insulin release. Modest hepatic XBP1s overexpression improved hyperglycemia in insulin-resistant mice partly through FOXO1 degradation, and p38-mediated enhancement of XBP1s activity restored euglycemia in severely obese diabetic mice. In adipose tissue, XBP1s overexpression promoted high-molecular-weight adiponectin multimerization and improved insulin sensitivity in lean and ob/ob mice.

On the inhibition side, kinase-inhibiting RNase attenuators (KIRAs) dampen the maladaptive outputs of IRE1α. In mice lacking Bax inhibitor-1, an endogenous negative regulator of IRE1α, excessive RNase activity drove NLRP3 inflammasome activation, beta-cell death and hyperglycemia; the RNase inhibitor STF-083010 reversed beta-cell failure and normalized the metabolic phenotype, and in obese mice it improved glucose tolerance while suppressing inflammatory adipose-tissue macrophages. More recently, KIRA8 restored sphingosine-1-phosphate lyase activity, improved AKT phosphorylation and glucose uptake in muscle cells, and ameliorated glucose metabolism in high-fat-diet-fed animals. Even a pomegranate flower polyphenol extract showed antidiabetic effects linked to inhibition of the hepatic IRE1α–XBP1–CHOP stress axis.

The authors are careful to stress that the pathway’s intrinsic bidirectionality creates a narrow therapeutic window: success will demand tissue-, dose-, duration- and output-selective modulation rather than blanket activation or suppression. Key unanswered questions include the stage-specific thresholds separating adaptive from harmful signaling, head-to-head comparisons of XBP1s activators, RNase inhibitors and kinase-domain modulators in the same models, and how well animal findings extrapolate to human disease. Still, the strategic position of IRE1α/XBP1 at the intersection of ER proteostasis, insulin signaling, inflammation, oxidative stress and beta-cell survival makes it, in the reviewers’ assessment, a credible next-generation target, one that could intervene where diabetes begins rather than merely where its symptoms end.

Subject of Research: The role of the IRE1α/XBP1 unfolded protein response pathway in type 2 diabetes and its potential as a therapeutic target

Article Title: Targeting the IRE1α/XBP1 pathway in type 2 diabetes mellitus: from ER stress signaling to therapeutic opportunity

Article References: Obafemi, O. T., Ayeleso, A. O., Ekundayo, B. E., Obafemi, B. A., Adewale, O. B., Lebelo, S. L., & Ntwasa, M. (2026). Targeting the IRE1α/XBP1 pathway in type 2 diabetes mellitus: from ER stress signaling to therapeutic opportunity. Molecular Biology Reports, 53(1), Article 1688. https://doi.org/10.1007/s11033-026-12876-7

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12876-7

Keywords: IRE1α, XBP1, unfolded protein response, endoplasmic reticulum stress, type 2 diabetes, insulin resistance, pancreatic beta cells, JNK signaling, NLRP3 inflammasome, RIDD, drug targets, metabolic disease

The endoplasmic reticulum is the cellular factory where newly made proteins are folded, modified, and quality-checked before they move on to their final destinations. Because protein folding is chemically demanding and exquisitely sensitive to the cellular environment, the ER is among the first organelles to falter when a cell is under oxidative assault. When misfolded proteins accumulate, the ER activates a rescue program known as the unfolded protein response, orchestrated by sensor proteins including PERK, IRE1α, and ATF6, together with the chaperone GRP78. If the stress is mild, this response restores balance. If it is prolonged or severe, the response turns lethal, ramping up the transcription factor ATF4 and its downstream partner CHOP, a protein that pushes stressed cells toward apoptosis.

Nicotine, the addictive alkaloid in tobacco, is a potent pro-oxidant that generates reactive oxygen species and depletes cellular antioxidant defenses. Earlier studies had implicated nicotine in testicular damage, showing reduced gametogenesis, altered steroidogenesis, and increased apoptosis in animal models, and had even linked nicotine exposure to ER stress in tissues such as the placenta and airway smooth muscle. What remained unclear was whether the ER stress pathway was a genuine mechanistic driver of nicotine-induced sperm dysfunction in the testis, and whether antioxidants could intervene at that specific signaling node rather than merely mopping up free radicals.

To answer these questions, the researchers worked with 48 two-month-old male Wistar albino rats, dividing them into six experimental groups: an untreated control, a nicotine-exposed group, three groups receiving nicotine together with melatonin, coenzyme Q10, or both compounds, and a group receiving the two antioxidants without nicotine. The design allowed the team to disentangle the toxic effects of nicotine from the protective effects of each supplement, and to test whether the combination offered any advantage over either compound alone. Sperm quality was assessed using standard andrological measures, while testicular tissue was examined for oxidative stress markers, ER stress gene expression, histopathology, and the immunohistochemical localization of key stress proteins.

The results were striking. Nicotine exposure significantly impaired sperm motility and membrane integrity while increasing abnormal sperm morphology, sperm mortality, and apoptosis, with all of these changes reaching high statistical significance. Biochemically, the nicotine-exposed testes showed elevated lipid peroxidation, a hallmark of oxidative damage to cellular membranes, alongside a collapse of antioxidant defenses, including reduced levels of glutathione, glutathione peroxidase, and catalase. In other words, nicotine created a double hit: it flooded the tissue with reactive oxygen species while simultaneously stripping away the enzymes and molecules that would normally neutralize them.

The critical new finding concerned the ER. In the nicotine group, the expression of a battery of ER stress-associated genes was markedly upregulated, including ATF4, ATF6, CHOP, GRP78, IRE1α, and PERK, the full cast of the canonical unfolded protein response. Immunohistochemistry confirmed increased CHOP immunoreactivity in the tissue, indicating that the pro-apoptotic arm of the ER stress response was not merely transcribed but translated into accumulated protein. This pattern suggests that nicotine pushes testicular cells past the adaptive phase of ER stress and into the maladaptive, death-signaling phase, providing a mechanistic bridge between oxidative damage and the observed sperm apoptosis.

Antioxidant treatment changed the picture substantially. Melatonin, the pineal hormone best known for regulating circadian rhythm but also a versatile direct and indirect antioxidant, and coenzyme Q10, an essential component of the mitochondrial electron transport chain and a lipid-soluble radical scavenger, each partially restored sperm quality and antioxidant capacity when given alongside nicotine. At the molecular level, the supplements significantly downregulated the ER stress gene panel, tamping down the expression of ATF4, ATF6, CHOP, GRP78, IRE1α, and PERK, and reducing CHOP immunoreactivity in the tissue. Histopathological analysis showed corresponding protection of testicular architecture, preserving the seminiferous environment in which sperm develop.

One detail of the data may prove particularly interesting to researchers. Coenzyme Q10 selectively enhanced XBP-1 immunoreactivity, a marker associated with the IRE1α branch of the unfolded protein response. Because the IRE1α–XBP-1 arm is generally considered adaptive, promoting protein folding capacity and cellular survival rather than death, this selective effect hints that coenzyme Q10 may not simply suppress ER stress wholesale but may help re-balance the response toward its protective branch. Melatonin, meanwhile, has previously been shown to modulate ER stress in contexts ranging from arsenite-induced neurotoxicity to fulminant hepatitis and testicular injury from bisphenol A and phthalates, and the new findings extend that mechanistic portfolio to nicotine-driven reproductive damage.

The authors are careful about scope. This is a rat study, with controlled dosing and a defined exposure window, and the leap from rodent testes to human male fertility is neither automatic nor trivial. The supplements produced partial rather than complete protection, which itself is informative: nicotine inflicts damage through multiple converging pathways, including vascular effects, hormonal disruption, and direct genotoxicity, so no single antioxidant can be expected to erase the harm. Data from the study are available upon reasonable request, and the work was supported by the Scientific Research Projects Coordination Unit of Hatay Mustafa Kemal University, with ethics approval from the institution’s Local Animal Ethics Committee.

Even with those caveats, the study carries real weight for a public health conversation that often treats smoking-related fertility damage as an afterthought. It identifies a specific, druggable signaling axis, the oxidative stress–ER stress–CHOP cascade, as a mediator of nicotine’s assault on sperm, and it demonstrates that two inexpensive, widely available compounds can intervene at that axis in a living animal. For the millions of smokers whose fertility may be quietly eroding, the message is not that a supplement can undo the damage of smoking, but that the biology of that damage is now understood well enough to be targeted, and that the surest intervention remains removing the toxin itself. Translational studies in human populations will be needed before melatonin or coenzyme Q10 can be recommended clinically, but as a proof of mechanism, this work sharpens the picture of how tobacco smoke reaches deep into the cellular machinery of reproduction.

Subject of Research: Nicotine-induced oxidative stress and endoplasmic reticulum stress signaling in rat testis and its attenuation by melatonin and coenzyme Q10

Article Title: Targeting the Nicotine-driven Maladaptive ER Stress Axis: Protective Roles of Melatonin and Coenzyme Q10 in Rat Testis

Article References: Eraslan Sakar, A., Yildiz, C., Coskun, N., Sengul, S. A., Akcakavak, F. K., Kutlu, T., Sayan, M., & Karabulut, D. (2026). Targeting the Nicotine-driven Maladaptive ER Stress Axis: Protective Roles of Melatonin and Coenzyme Q10 in Rat Testis. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02235-z

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02235-z

Keywords: nicotine, endoplasmic reticulum stress, melatonin, coenzyme Q10, sperm quality, male fertility, oxidative stress, testis, apoptosis, unfolded protein response, CHOP, rat model

The researchers began with a straightforward hypothesis grounded in clinical observation. Solar lentigines are characterized by persistent basal hyperpigmentation, meaning that the deepest layer of the epidermis remains loaded with melanin long after the original sun exposure that triggered it. They proposed that a sustained stress response centered on IRE1α, a sensor protein embedded in the endoplasmic reticulum membrane, could act on both sides of the pigment equation at once. IRE1α is best known as a key initiator of the unfolded protein response, a cellular quality-control program that activates when misfolded proteins accumulate. When the stress is brief, the response is protective; when it becomes chronic, it can push cells toward senescence, a state of permanent growth arrest.

To test the idea, the team combined human tissue analysis with mechanistic experiments in cell culture. They examined paired samples of lesional and non-lesional skin from patients with solar lentigines, work approved by the Institutional Review Board of Severance Hospital, and complemented the histology with two laboratory models: MNT-1 melanocytes, the pigment-producing cells of the skin, and HaCaT keratinocytes, the cells that form the bulk of the epidermis and normally receive and degrade transferred melanosomes. Crucially, the keratinocyte model included a doxycycline-inducible system as well as constitutive IRE1α expression, allowing the researchers to switch the stress pathway on at will and observe the consequences in a controlled manner.

The tissue findings set the stage. In lesional epidermis, the investigators observed dense accumulations of stage-IV melanosomes, the fully mature, heavily pigmented organelles that melanocytes manufacture and hand off to keratinocytes. Alongside this pigment load, the stressed skin showed elevated levels of IRE1α and p16, a canonical marker of cellular senescence. This co-occurrence was the first hint that the two phenomena, aging-like growth arrest and pigment retention, might share a common driver rather than being parallel but independent consequences of sun damage.

Experiments in the cell models then dissected the mechanism in detail. When the researchers sustained IRE1α signaling, cell proliferation dropped and the senescence markers p16 and p21 rose, confirming that chronic endoplasmic reticulum stress is sufficient to push these epidermal cells into a senescent state. In the melanocytes, the consequences for pigmentation were direct and measurable: IRE1α activation increased tyrosinase activity, the rate-limiting enzymatic step of melanin synthesis, and raised total melanin content. The cells also produced more melanosomes, and those melanosomes were larger than normal, expanding the raw supply of pigment available for transfer to surrounding keratinocytes.

The second half of the dual-hit mechanism emerged from the keratinocyte experiments. Keratinocytes are not passive pigment containers; they are supposed to degrade the melanosomes they receive through lysosomal pathways, a process sometimes described as melanophagy. Under sustained IRE1α signaling, that degradation slowed markedly. The researchers quantified intracellular melanosomes and found they accumulated because they were being broken down more slowly, not because more were arriving. Probing the lysosomal system, they detected diminished LysoTracker signal, indicating reduced lysosomal acidity, along with reduced maturation of cathepsin-B, a key degradative enzyme that requires an acidic environment to become fully active. Autophagic flux, measured with a mRFP–GFP–LC3 reporter that distinguishes early autophagosomes from mature autolysosomes, was also compromised, with fewer autolysosomes forming.

Together, these results sketch a coherent pathological circuit. Chronic IRE1α signaling in melanocytes ramps up melanogenesis, flooding the epidermis with pigment, while the same stress pathway in keratinocytes weakens the lysosomal machinery responsible for clearing that pigment away. The senescent state that accompanies the stress response likely stabilizes the situation, since senescent cells persist in tissue rather than being replaced, maintaining the altered signaling environment over time. The net effect is that pigment is produced faster and cleared more slowly, exactly the combination needed to explain the dense, persistent basal hyperpigmentation that defines solar lentigines.

The study also points toward intervention. The researchers tested two agents: verapamil, a calcium channel blocker better known as a cardiovascular drug, and STF083010, a selective inhibitor of the IRE1α RNase domain, the enzymatic activity through which IRE1α transmits its stress signal. Both compounds lessened melanosome accumulation in the keratinocyte model and partially restored degradative function. While the restoration was partial, the finding is significant because it demonstrates that the pigment-retention phenotype is not irreversible and that the IRE1α–lysosome axis is a plausible therapeutic target. Existing treatments for solar lentigines, such as laser therapy and topical depigmenting agents, aim primarily at melanin production or destruction; a strategy that instead restores the clearance machinery would represent a fundamentally different approach.

The broader implications extend beyond cosmetically visible age spots. The unfolded protein response has been implicated in a wide range of age-related tissue changes, and this study adds a vivid example of how a single stress sensor can couple senescence to a tissue-specific functional outcome, in this case pigmentation. The work also highlights melanophagy as an underappreciated control point in skin color biology. Most research on hyperpigmentation has focused on melanocytes and their synthetic output, but the fate of melanosomes after transfer is equally decisive, and lysosomal acidification and cathepsin maturation emerge from this study as actionable levers. If the findings hold up in further clinical studies, modulating IRE1α activity or supporting lysosomal function could inform the development of treatments not only for solar lentigines but potentially for other disorders of pigment retention.

The research, funded by the National Research Foundation of Korea, Yonsei University College of Medicine and the Korea Health Technology R&D Project, was published as an open-access article and is citable under DOI 10.1007/s00018-026-06389-6. Its central message is elegant in its economy: one stress pathway, acting chronically, produces pigment faster and disposes of it more slowly, while locking the affected cells into senescence. For the millions of people who develop these stubborn brown patches, the study offers something more concrete than a new description of the problem, namely a defined molecular axis that can, at least in laboratory models, be pharmacologically nudged back toward balance. Translating that laboratory result into safe and effective clinical therapy will require further work, but the identification of the IRE1α and lysosome axis as a coupled driver of senescence and pigment retention gives the field a clear and testable direction.

Subject of Research: Chronic endoplasmic reticulum stress linking cellular senescence to persistent skin hyperpigmentation in solar lentigines

Article Title: Chronic ER stress couples cellular senescence with pigment retention

Article References: Hwang, S., Kim, J. Y., Lee, E. J., Oh, D., Bae, Y. J., Kwon, I. J., Park, S., Seo, H. R., Alqahtani, J., Lee, J., & Oh, S. H. (2026). Chronic ER stress couples cellular senescence with pigment retention. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06389-6

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06389-6

Keywords: solar lentigo, IRE1α, unfolded protein response, ER stress, cellular senescence, melanophagy, melanogenesis, lysosomal acidification, keratinocytes, melanocytes, p16, skin aging

Lifeguard, also called Fas Apoptotic Inhibitory Molecule 2 or FAIM2, belongs to an evolutionarily conserved family of transmembrane proteins that regulate programmed cell death. Previous work by the same research group and others showed that the protein is present at elevated levels in human breast cancer tissues and cell lines, where it blocks apoptosis triggered through the Fas death receptor. Elevated FAIM2 expression has also been linked to tumor development and poor clinical outcomes in colorectal cancer, and to growth and bone metastasis in non-small cell lung cancer. Because the protein concentrates in the endoplasmic reticulum and Golgi apparatus, the researchers suspected it might do more than simply shield cells from death signals; it might also shape how cells respond to stress within the secretory pathway itself.

To probe this question, the team, led by Inga Nebel and Vesna Bucan of Hannover Medical School together with colleagues, used two contrasting cell models: MDA-MB-231, an aggressive triple-negative breast cancer line that lacks the three major therapeutic targets, and MCF10A, a non-tumorigenic mammary epithelial line that serves as a normal reference. Triple-negative breast cancer is among the hardest breast cancers to treat, and drug resistance remains a central clinical challenge, so understanding molecular survival factors in this subtype carries particular weight. The researchers silenced Lifeguard using a small interfering RNA and then measured what happened to endoplasmic reticulum stress-associated genes and intracellular calcium over the following two days.

Before the functional experiments, the team built a three-dimensional computational model of the human Lifeguard protein using the SWISS-MODEL homology server. The predicted structure revealed seven transmembrane domains, a heptahelical architecture consistent with Lifeguard’s membership in the LFG/TMBIM family of membrane-associated proteins. Quality metrics such as the QMEAN Z-score and local quality estimates supported the overall plausibility of the model, although some regions showed lower confidence, as is common for predictions of small multi-pass membrane proteins that are difficult to crystallize. The authors are careful to note that this model illustrates the protein’s likely membrane topology and was not used for any structure-function conclusions; no experimentally resolved structure of the full protein yet exists.

The silencing experiments produced a clear and time-dependent effect. Untreated MDA-MB-231 cancer cells carried substantially higher basal Lifeguard mRNA levels than the non-tumorigenic MCF10A cells, confirming the overexpression pattern seen previously in tumor tissue. After transfection with the Lifeguard-specific siRNA, mRNA levels in the cancer cells dropped noticeably by 24 hours and fell sharply by 48 hours. In MCF10A cells, which start from a much lower baseline, the reduction was more moderate. This cell-type difference matters, because it suggests that the molecular consequences of targeting Lifeguard may be concentrated in tumor cells rather than evenly distributed between cancerous and healthy tissue.

Calcium emerged as an early indicator of change. Using a fluorescence-based calcium assay with the Calbryte-520 dye, the researchers observed a progressive reduction in intracellular calcium-associated fluorescence in MDA-MB-231 cells at 24 and 48 hours after Lifeguard siRNA treatment. The observation fits neatly with earlier work showing that Lifeguard inhibits Fas ligand-induced calcium release from the endoplasmic reticulum, a step that is mandatory for apoptosis in so-called type II cells. Calcium signaling from the endoplasmic reticulum sits at the crossroads of cellular homeostasis, stress responses, and cell death, so any perturbation of this balance could influence how tumor cells cope with therapeutic pressure.

The gene expression analysis, performed with a Qiagen RT2 Profiler PCR Array covering endoplasmic reticulum stress genes, revealed a distinctive molecular signature in the cancer cells. Forty-eight hours after Lifeguard silencing, three genes were upregulated in MDA-MB-231 cells: CREB3L3, a transcription factor of the endoplasmic reticulum stress network; SREBF1, a master regulator of lipid metabolism; and INHBE, a pathway signature gene. At the same time, several genes were downregulated, including EDEM1, which participates in protein folding quality control by targeting misfolded proteins for degradation; HSPA2, a molecular chaperone that binds unfolded proteins; and RRM2, which drives nucleotide metabolism and DNA synthesis. In MCF10A cells the changes were milder, with ASNS and RRM2 reduced but most other genes unaffected.

Interpreting this pattern, the authors propose that Lifeguard silencing is associated with a coordinated response spanning endoplasmic reticulum stress, lipid metabolism, protein homeostasis, and proliferation. The drop in RRM2 in both cell lines hints at connections to nucleotide synthesis and cell division, while the differential behavior of ASNS points to a cell-type-specific metabolic stress response. The researchers also situate their findings within a broader literature: FAIM2-associated regulatory networks have been described in hepatocellular carcinoma and lung cancer, and a NFKB1-miR-612-FAIM2 pathway has been implicated in neurofibromatosis type 1, showing that the gene can be controlled through diverse transcriptional and noncoding RNA mechanisms depending on the cellular context. Pan-cancer analyses have additionally identified FAIM2 as a tumor-associated and prognostically relevant molecule, and its promoter has been found hypermethylated in pancreatic cancer cohorts.

The authors are notably candid about the limits of their study. Only one cancer cell line and one normal comparator were examined, which constrains generalizability, and the silencing was verified at the mRNA level without demonstrating a corresponding depletion of Lifeguard protein. Because of this, the observed changes in calcium fluorescence and gene expression must be treated as associations rather than proof that loss of the protein directly causes the downstream effects. The siRNA treatment itself could conceivably contribute to some of the measured responses. The team therefore calls for follow-up work using quantitative protein measurements, multiple independent siRNA sequences, functional rescue experiments, and direct apoptosis assays to establish causality.

Even with those caveats, the study adds a meaningful dimension to a protein best known as a death-receptor antagonist. By linking Lifeguard to calcium handling and to a specific set of endoplasmic reticulum stress and metabolic genes in triple-negative breast cancer cells, it sketches a possible route by which tumor cells maintain homeostasis under pressure and evade chemotherapy-induced death. If future experiments confirm that Lifeguard protein depletion drives these changes, the protein could become an attractive target for combination therapies designed to sensitize resistant tumors to apoptosis. For now, the message is one of cautious promise: a membrane protein once viewed purely as a brake on cell death appears to be entangled with the stress physiology of the endoplasmic reticulum, and untangling that relationship may reveal new vulnerabilities in one of the most stubborn forms of breast cancer.

Subject of Research: The role of the anti-apoptotic protein Lifeguard (FAIM2) in regulating endoplasmic reticulum stress responses and calcium homeostasis in breast cancer cells

Article Title: Regulation of ER Stress‐Associated Gene Expression by Lifeguard in Human Breast Cancer Cells

Article References: Nebel, I., Strauß, S., Schlottmann, F., Herrmann, L. M., Vogt, P. M., & Bucan, V. (2026). Regulation of ER Stress‐Associated Gene Expression by Lifeguard in Human Breast Cancer Cells. Cancer Reports, 9(10), Article e70687. https://doi.org/10.1002/cnr2.70687

Image Credits: AI Generated

DOI: 10.1002/cnr2.70687

Keywords: Lifeguard, FAIM2, breast cancer, triple-negative breast cancer, endoplasmic reticulum stress, apoptosis, calcium signaling, siRNA, gene expression, drug resistance, MDA-MB-231, unfolded protein response

Hepatocellular carcinoma, the most common primary liver cancer, remains one of the world’s deadliest malignancies. It is the third leading cause of cancer-related death globally, and although viral hepatitis, alcohol consumption, aflatoxin exposure and poor diet all contribute to its development, the clinical picture is dominated by a single grim statistic: most patients are diagnosed at an advanced stage, when surgical options such as resection, transplantation or ablation are no longer viable. Approved drug therapies for advanced disease, including multikinase inhibitors such as sorafenib, lenvatinib and cabozantinib, and antibody combinations built around agents like bevacizumab and atezolizumab, have extended survival only modestly. The field’s persistent hunger for molecules with new structures and new mechanisms is what makes the KGA-1002 story notable.

The compound’s origin lies in the chemistry of Artemisia, the genus that gave the world artemisinin. Sesquiterpenoid dimers, molecules in which two sesquiterpene units are joined, have repeatedly shown stronger antitumor activity than their monomeric parents, but their scarcity in plants has historically blocked serious drug development. The Kunming group sidestepped that bottleneck through biomimetic synthesis: using a Diels-Alder reaction, they assembled KGA-1002 from dehydrocostus lactone, an abundant natural sesquiterpenoid, on a ten-gram scale. The resulting dimer inhibited the proliferation of three hepatocellular carcinoma cell lines with IC50 values of 5.9, 6.9 and 6.3 micromolar against HepG2, Huh7 and SK-Hep-1 cells respectively, outperforming sorafenib and beating the parent monomer dehydrocostus lactone by roughly five- to seven-fold.

Identifying what a small molecule actually touches inside a cell is the hardest part of natural product pharmacology, and the team attacked it with a battery of orthogonal techniques. A drug affinity responsive target stability assay, which exploits the fact that ligand-bound proteins resist enzymatic digestion, flagged a protein band that survived pronase treatment only in the presence of KGA-1002. Mass spectrometry of that band yielded 49 candidate proteins, which transcriptomic profiling and bioinformatics narrowed to six. The decisive experiment was genetic: when the researchers silenced each candidate in liver cancer cells, only knockdown of GRP94, the endoplasmic reticulum-resident member of the heat shock protein 90 family, blunted the drug’s antiproliferative and anti-migratory effects. Surface plasmon resonance then measured direct binding, with a dissociation constant of 454 nanomolar, and a cellular thermal shift assay confirmed that KGA-1002 stabilizes GRP94 inside cells.

The structural detail goes further than most target-identification studies dare. KGA-1002 carries an alpha, beta-unsaturated carbonyl motif, a well-known covalent warhead, and molecular dynamics simulations showed that this group is essential for stabilizing the GRP94-ligand complex. Mass spectrometric sequencing of the treated protein revealed a peptide whose mass had increased by exactly the molecular weight of the drug, and secondary fragmentation localized the covalent bond to serine 106, a hydroxyl-bearing residue ideally positioned for nucleophilic attack on the unsaturated carbonyl. When the team mutated serine 106 to alanine, binding affinity collapsed from 522 nanomolar to 461 micromolar, a nearly thousand-fold loss. Critically, KGA-1002 did not stabilize the cytosolic family members HSP90alpha or HSP90beta, whose indiscriminate inhibition has doomed pan-HSP90 drugs in clinical trials. That isoform selectivity, aided by an additional contact with GRP94-specific asparagine 276, is arguably the compound’s most clinically relevant property.

With the target pinned down, the downstream biology fell into place. GRP94’s day job is folding, assembling and trafficking client proteins inside the endoplasmic reticulum, and its inhibition floods the ER lumen with misfolded polypeptides. Transcriptomic analysis of treated cells showed enrichment of ER-related pathways, upregulation of stress genes such as ERN1, ATF4 and DDIT3, and downregulation of ER trafficking genes. The canonical unfolded protein response sensors PERK and IRE1, normally held inactive by the chaperone BiP, were activated, driving expression and nuclear translocation of the death-promoting transcription factors XBP1 and CHOP. Because GRP94 also buffers calcium in the ER, the drug produced a dose-dependent rise in intracellular calcium, climbing to nearly 98 percent calcium-positive cells at 7.5 micromolar in both SK-Hep-1 and Huh7 lines. The unfolded protein response, in other words, was not a side effect but the engine of tumor killing.

The most novel mechanistic finding concerns AKT, the kinase at the heart of the PI3K survival pathway. KGA-1002 lowered AKT protein levels without touching its mRNA, and cycloheximide chase experiments showed the drug accelerating AKT degradation; proteasome and lysosome inhibitors each partially rescued the protein, implicating both disposal routes. The explanation proved to be a chaperone-client relationship: GRP94 physically holds AKT, and pulldown assays demonstrated that KGA-1002 disrupts that interaction, both in cell lysates and with purified proteins. Destabilized AKT could no longer phosphorylate SKP2, the F-box substrate-recognition protein of an E3 ubiquitin ligase that normally tags the cell cycle brake P21 for destruction. Deprived of AKT’s stabilizing phosphorylation, SKP2 itself was degraded through the proteasome, P21 accumulated in the nucleus, and the cells arrested in G0/G1 and died. Clinical databases reinforced the story: both GRP94 and SKP2 are overexpressed in hepatocellular carcinoma tissues and correlate with poor survival.

The death program did not stop at apoptosis. With AKT signaling crippled, the antioxidant defenses of the cell, maintained through the AKT-mTOR axis, Nrf2 and GSK-3beta, eroded, and reactive oxygen species accumulated. Mitochondrial membrane potential collapsed, lipid peroxidation measured as malondialdehyde rose, the ferroptosis gatekeeper GPX4 fell, and labile iron climbed, all hallmarks of ferroptosis, the iron-dependent form of regulated cell death. The ROS scavenger N-acetylcysteine and the ferroptosis inhibitor liproxstatin-1 each blunted these effects, confirming causality. KGA-1002 thus kills liver cancer cells along two converging routes, ER stress-driven apoptosis and AKT-dependent ferroptosis, both traceable to a single upstream lesion at GRP94.

In vivo, the compound held up. In nude mice bearing subcutaneous SK-Hep-1 tumors, intraperitoneal KGA-1002 at 15, 30 and 60 milligrams per kilogram over 60 days shrank tumors by 44.1, 52.1 and 53.5 percent, with the top dose matching sorafenib; direct intratumoral injection performed even better, reaching 61.6 percent inhibition. Tumors from treated animals showed reduced Ki67 staining and elevated phosphorylated IRE1 and PERK, confirming that the ER stress mechanism operates in living tissue. The decisive target-validation experiment came from xenografts grown from GRP94-knockdown cells: with the target partially removed, the drug’s antitumor effect and its suppression of Ki67 were significantly weakened, establishing that KGA-1002’s efficacy is GRP94-dependent. Safety readings were reassuring, with no weight loss, behavioral changes, liver or kidney function abnormalities, and no histopathological organ damage even at 150 milligrams per kilogram in a separate subacute study.

The study’s authors are careful about scope, and so should readers be. The work rests on cell lines and subcutaneous mouse models, not orthotopic liver tumors or patients, and a selectivity index of roughly 1.5 to 1.7 over normal hepatocytes, while adequate, leaves room for optimization. Yet the conceptual payoff is substantial: GRP94 has been implicated in breast cancer metastasis and multiple myeloma, and the authors note it is also overexpressed in colon, esophageal and bladder cancers, so a validated, covalent, isoform-selective inhibitor scaffold is a tool the wider oncology community can build on. By showing exactly where the molecule docks, which residue it attacks, and how that single molecular event cascades through protein folding, calcium handling, AKT stability, SKP2 degradation and ferroptosis, the Kunming team has delivered something rarer than another cytotoxic natural product: a mechanistically coherent proof that GRP94 is a druggable vulnerability in liver cancer, and a lead compound engineered to exploit it.

Subject of Research: A selective GRP94 inhibitor derived from a guaianolide sesquiterpenoid dimer as a therapeutic agent against hepatocellular carcinoma

Article Title: Guaianolide dimer KGA-1002 targets GRP94 and triggers unfolded protein response-associated degradation of SKP2/AKT axis as a novel antihepatoma agent

Article References: Li, Q.-H., Li, T.-Z., Wang, Y.-C., Huang, X.-Y., Ma, W.-J., Li, F.-J., Huang, F.-D., Hu, M.-M., & Chen, J.-J. (2026). Guaianolide dimer KGA-1002 targets GRP94 and triggers unfolded protein response-associated degradation of SKP2/AKT axis as a novel antihepatoma agent. Journal of Advanced Research, 88, 1077-1093. https://doi.org/10.1016/j.jare.2026.01.010

Image Credits: AI Generated

DOI: 10.1016/j.jare.2026.01.010

Keywords: hepatocellular carcinoma, GRP94, KGA-1002, guaianolide dimer, unfolded protein response, AKT, SKP2, P21, ferroptosis, endoplasmic reticulum stress, natural products, drug discovery

The team focused on the mitochondrial calcium uniporter, or MCU, a channel protein embedded in the inner mitochondrial membrane that ferries calcium ions from the cytosol into the mitochondrial matrix. In mammals, the MCU complex includes pore-forming MCU proteins regulated by accessory components called MICU and EMRE, and decades of work have established that mitochondrial calcium homeostasis is essential for energy production, cell survival, and the decision between life and death. Plants possess their own family of MCU proteins: Arabidopsis carries six putative MCU orthologs, each with a conserved transmembrane domain, a pore loop, and a signature DVME sequence. Previous studies had shown that MCU1, MCU2, MCU3, and MCU5 localize to mitochondria, while MCU6 can target both mitochondria and chloroplasts, and that a triple mutant lacking MCU1, MCU2, and MCU3 shows reduced calcium uptake in roots. What remained unknown was what happens to the entire cell when this calcium gatekeeping system is disturbed.

To answer that question, the researchers first confirmed where the six MCU proteins reside and when they are active. Using fluorescent YFP tags in stable transgenic plants, they observed that the MCU proteins colocalize with mitochondrial markers in leaf and root cells. GUS staining revealed tissue-specific expression patterns: all six genes are active in the root stele, MCU3 is highly expressed in the root apex and cortex, MCU6 dominates the basal meristem, and MCU3, MCU4, and MCU6 are expressed in guard cells. This map of expression hinted that different MCU family members might play specialized roles in different tissues, but also that they share a common job as mitochondrial calcium channels.

The critical technical advance came from genetics. Because the six MCU genes are functionally redundant, the team crossed single mutants to build a sextuple knockdown line, mcu1-6, in which all six genes are expressed at reduced levels. They also created plants that massively overexpress MCU2, with one line showing a ninefold increase in transcript abundance. To watch calcium dynamics in real time, they targeted the calcium-sensitive luminescent reporter aequorin to the mitochondrial matrix and to the cytosol, then challenged seedlings with mannitol, which mimics drought-induced osmotic stress, and sodium chloride, which imposes salt stress. The results were unambiguous. Overexpressing MCU2 amplified the mitochondrial calcium surge, producing higher peak amplitudes and larger response curves, while the sextuple mutant blunted the response, reducing peak amplitudes by an average of 21 percent under mannitol and 26 percent under salt. Crucially, cytosolic calcium signals were unchanged in both lines, demonstrating that MCUs specifically tune mitochondrial calcium uptake without substantially buffering the cytosolic calcium wave that sweeps through stressed cells.

With the calcium phenotype established, the researchers turned to transcriptomics to see how the cell responds. They compared gene expression in the MCU2 overexpression line and the sextuple mutant against two reference conditions: untreated wild type and wild type treated with antimycin A, a drug that blocks the mitochondrial electron transport chain and classically induces the mitochondrial retrograde response. The comparison produced a surprise. Both MCU-perturbed genotypes activated a broad transcriptional program affecting mitochondrial proteostasis—genes encoding mitoribosomal proteins, oxidative phosphorylation complex subunits, the mitochondrial protein import machinery, and matrix proteases were all upregulated. Chaperone genes from four different compartments were induced as well: mitochondrial Hsp70 proteins, cytosolic chaperones, endoplasmic reticulum chaperones, and chloroplast chaperones. Western blots confirmed that mtHsp70 protein accumulated in the overexpression and knockdown lines. None of this multi-compartment chaperone induction appeared in antimycin-treated plants, and the alternative oxidase genes that normally mark the antimycin response stayed silent in the MCU mutants. In other words, disturbing mitochondrial calcium homeostasis triggers a stress program that is fundamentally different from the well-known retrograde response to respiratory chain damage.

The team interprets this pattern as the simultaneous activation of multiple compartment-specific unfolded protein responses. When proteins fail to fold properly in the mitochondrial matrix, the cell does not merely repair the mitochondrion; it appears to mobilize quality-control machinery in the cytosol, the ER, and the chloroplast as well. The researchers suggest that the underlying trigger is likely proteotoxic stress caused by disturbed mitochondrial translation. Supporting this idea, immunoblots showed that mitochondrially encoded subunits of respiratory complexes III, IV, and V—COB, COX1, ATP4, and ATP8—were reduced in the MCU-perturbed plants, while some nuclear-encoded subunits accumulated, creating a stoichiometric imbalance between the two genomes that supply the respiratory chain. This kind of mitonuclear protein imbalance is a classic activator of the mitochondrial unfolded protein response in animals, and the plant transcriptional profile resembled the interorganellar proteostasis program described in yeast, suggesting deep evolutionary conservation of this alarm system.

But the story did not end with transcription. Quantitative mass spectrometry of the proteome revealed that roughly half of the differentially abundant proteins in the sextuple mutant did not follow their transcript levels. Most strikingly, of the 194 cytosolic ribosomal protein genes whose abundance changed, about 58 percent showed reduced protein despite elevated mRNA. The same paradox appeared for chloroplast and mitochondrial ribosomal proteins and for pentatricopeptide repeat proteins, tetratricopeptide repeat proteins, and pseudouridine synthases—proteins that perform RNA editing and translation inside organelles. To investigate this apparent post-transcriptional repression, the researchers performed polysome profiling, separating actively translated mRNAs on polysomes from poorly translated ones on monosomes. While antimycin treatment caused a dramatic global shift from polysomes to monosomes, the MCU-perturbed plants showed only a mild global shift. Instead, translational efficiency analysis revealed a highly selective repression: genes involved in mitochondrial RNA metabolism and RNA modification lost translational efficiency in both the overexpression line and the sextuple mutant, with about 81 percent of RNA modification transcripts showing low translational efficiency. More than half of all transcriptionally induced cytosolic ribosomal protein mRNAs were also translationally repressed.

This selective translation program points to specific molecular effectors. In mammalian cells, the kinase GCN2 phosphorylates the translation initiation factor eIF2α to dampen protein synthesis during stress, while the TOR pathway senses energy status. The proteomic and immunoblot data told an unexpected tale: in the MCU-perturbed plants, eIF2α protein abundance and its phosphorylated form were both reduced, along with several translation initiation components, while TOR and the energy-sensing kinases KIN10 and KIN11 were largely unaffected. Antimycin treatment produced the opposite signature—increased KIN10 and KIN11 phosphorylation and reduced TOR, with no change in eIF2α. The authors propose that these two pathways mediate distinct types of mitochondrial stress: the TOR-S6K energy-sensing module handles the short-term, acute crisis caused by electron transport chain poisoning, whereas the eIF2α pathway manages the long-term, mild proteotoxic stress of chronic calcium imbalance. Counterintuitively, reducing eIF2α phosphorylation may be protective, preventing a catastrophic shutdown of protein synthesis during prolonged stress—an adaptive mechanism recently proposed in mammalian cells that now appears to operate in plants as well.

The physiological consequences of this molecular storm were visible to the naked eye. Plants with impaired MCU-controlled calcium homeostasis grew more slowly, with reduced leaf area that correlated with MCU2 expression levels in the overexpression lines. They also senesced prematurely, yellowing their older leaves weeks before wild type plants, and the timing of senescence tracked MCU2 dosage. Under osmotic stress induced by mannitol, both the overexpression lines and the sextuple mutant were significantly more sensitive than wild type, with markedly reduced fresh weight. These phenotypes establish a direct link between mitochondrial calcium homeostasis and the core stress biology traits of growth, aging, and stress resistance, and they suggest that the cross-compartmental proteostatic response is not merely a curiosity of gene expression but a determinant of plant fitness.

The study does have acknowledged limitations. The aequorin reporter lacks the sensitivity to resolve basal calcium levels or subtle changes after antimycin treatment, so modest differences in resting mitochondrial calcium cannot be excluded. The upstream regulators of MCU-mediated calcium signaling remain undefined, and future work with established calcium influx mutants such as osca and moca1 will be needed to position the uniporters within the broader calcium signaling hierarchy. The detailed molecular analysis also focused on a single high-expression MCU2 overexpression line, leaving open the possibility that individual MCU isoforms have distinct intrinsic activities. Even so, the findings provide a compelling new framework: mitochondrial calcium homeostasis, mitochondrial translation, and cellular proteostasis are woven together through an interconnected organelle quality control network that integrates transcriptional activation with selective translational repression. As climate change intensifies drought and salinity stress on crops, understanding and potentially engineering this calcium-triggered proteostatic alarm could offer new genetic targets for breeding more resilient plants.

Subject of Research: Mitochondrial calcium homeostasis and cross-compartmental proteostatic signaling in Arabidopsis

Article Title: Perturbation of mitochondrial Ca2+ homeostasis activates cross-compartmental proteostatic response in Arabidopsis

Article References: Perturbation of mitochondrial Ca2+ homeostasis activates cross-compartmental proteostatic response in Arabidopsis. (n.d.). https://doi.org/10.1007/s44154-026-00314-4

Image Credits: AI Generated

DOI: 10.1007/s44154-026-00314-4

Keywords: mitochondria, calcium signaling, mitochondrial calcium uniporter, Arabidopsis, unfolded protein response, proteostasis, retrograde signaling, eIF2α, translation regulation, plant stress, ribosomal proteins, senescence

The findings matter because Phytophthora species, which include the agent of potato late blight, continue to devastate crops worldwide. Classical resistance genes often lose effectiveness as pathogens rapidly evolve new virulence, prompting plant scientists to look instead at susceptibility genes, host factors that pathogens exploit to establish infection. Disrupting these genes can deliver durable, broad-spectrum resistance. RTP1, which encodes a protein embedded in the endoplasmic reticulum membrane, was previously identified as just such a susceptibility factor: mutant plants lacking RTP1 show enhanced resistance to multiple biotrophic pathogens, accompanied by faster cell death, stronger oxidative bursts, and elevated expression of defense genes. What remained unknown was which downstream molecules actually carry out the cell death and immune signaling that RTP1 normally restrains.

The answer, according to the new study, is BI-1, a conserved regulator of programmed cell death that resides in the endoplasmic reticulum. When the researchers inoculated wild-type and rtp1 mutant seedlings with P. parasitica zoospores and tracked gene expression in roots over the first 24 hours of infection, they found that BI-1 transcript levels rose in both genotypes, but the induction was far stronger in the rtp1 mutants, particularly at 3, 6, and 12 hours post-inoculation. This timing coincides with the pathogen’s early biotrophic colonization phase, during which it penetrates root cells, forms appressoria, and develops haustorium-like structures. The data suggested that RTP1 normally acts to suppress BI-1 expression precisely when the plant most needs it.

To connect BI-1 to the accelerated cell death seen in rtp1 plants, the team used a fluorescein diacetate staining assay, which measures cell viability by fluorescence intensity. As expected, infected rtp1 roots showed significantly higher cell death rates than wild-type Col-0 roots. Strikingly, when the researchers generated rtp1 bi-1 double mutants, the excessive cell death largely disappeared. This genetic epistasis experiment demonstrated that BI-1 is essential for the cell death phenotype triggered by loss of RTP1, placing BI-1 downstream of the susceptibility factor in the cell death regulatory hierarchy. It echoes earlier work from the same group showing that the vacuolar processing enzyme gamma-VPE is similarly required for rtp1-mediated cell death, hinting that RTP1 coordinates parallel branches of cell death signaling located in different cellular compartments.

The importance of BI-1 extended well beyond cell death into full-blown immunity. Microscopic examination of roots infected with a GFP-tagged P. parasitica strain revealed less pathogen colonization in rtp1 mutants than in wild type, but the rtp1 bi-1 double mutants were colonized more heavily than rtp1 plants alone. Quantitative PCR measurements of pathogen biomass confirmed the pattern: the reduced fungal-like pathogen load characteristic of rtp1 mutants was substantially restored in the double mutants between 3 and 12 hours post-inoculation. At the later necrotrophic stage, seven days after inoculation, more than 60 percent of rtp1 seedlings remained healthy while over 83 percent of wild-type plants were heavily infected; the double mutants lost much of this protection, showing significantly elevated seedling death rates.

The molecular signature of the immune response told the same story. In infected rtp1 plants, the ER stress-responsive immune genes WRKY33, CBP60g, and MYB51, along with the defense marker PR1, are strongly induced. In the rtp1 bi-1 double mutants, this induction was markedly reduced. The team also tested the oxidative burst triggered by flg22, a conserved fragment of bacterial flagellin that activates pattern-triggered immunity. While rtp1 mutants mounted a stronger transient reactive oxygen species burst than wild type, the double mutants showed an essentially abolished response in a luminol-based chemiluminescence assay. Together, these results establish BI-1 as an integral node linking RTP1 to both immune gene expression and ROS production.

Independent evidence that BI-1 acts positively in defense came from overexpression experiments. Transient expression of BI-1 in Nicotiana benthamiana leaves before inoculation produced significantly smaller infection lesions and lower pathogen biomass at 48 hours. In Arabidopsis, transgenic plants overexpressing BI-1 developed fewer water-soaked lesions on detached leaves and supported less pathogen growth in both leaves and roots, while bi-1 loss-of-function mutants were more susceptible than wild type and showed weakened induction of the same ER stress-responsive immune genes. The immune function of BI-1 appears conserved across plant-pathogen systems: overexpression enhances resistance to rice blast, silencing of the wheat ortholog increases susceptibility to stripe rust, and BI-1 cooperates with the IRE1/bZIP60 pathway to restrict viral movement in plants.

Perhaps the most mechanistically revealing result concerns how RTP1 antagonizes BI-1. The two proteins physically interact, and when the researchers co-expressed tagged versions of both in Nicotiana benthamiana, BI-1 protein accumulation dropped by roughly 57 percent at two days and 62 percent at three days after infiltration. Critically, treating the leaves with MG132, a proteasome inhibitor, failed to restore BI-1 levels, indicating that RTP1 promotes BI-1 degradation through a proteasome-independent route. Given that BI-1 interacts with the autophagy protein ATG6 and both localize to the ER, the authors propose that RTP1 may steer BI-1 toward vacuolar or autophagic degradation. Intriguingly, RTP1 was recently shown to destabilize another ER-localized immune protein, the cytochrome P450 enzyme CYP71B3, suggesting a recurring strategy in which this susceptibility factor suppresses defense by depleting ER-localized immune components.

The study also clarified how BI-1 transcription is driven during infection. The BI-1 promoter contains G-box elements recognized by basic leucine zipper transcription factors, along with canonical ER stress response elements. Induction of BI-1 upon infection was blunted in bzip28 and bzip60 single mutants and most severely attenuated in the bzip28 bzip60 double mutant, pointing to redundant roles for these two unfolded protein response transducers. Dual-luciferase reporter assays showed that the activated forms of bZIP28 and bZIP60 each activated the BI-1 promoter, with co-expression of both producing an even stronger response, and yeast one-hybrid assays confirmed direct physical binding of each transcription factor to the promoter. BI-1 thus sits under dual control: transcriptionally activated by the ER stress sensing pathway and post-translationally dismantled by RTP1.

Taken together, the work establishes the RTP1-BI-1 module as a pivotal interface connecting ER stress perception to immune execution. Because BI-1 and gamma-VPE operate in distinct compartments yet both mediate rtp1-driven immunity, RTP1 emerges as a central hub orchestrating multiple ER stress-associated cell death pathways. For crop breeders, the implications are tangible: manipulating the RTP1-BI-1 axis, or the bZIP60 and bZIP28 transcription factors that feed into it, could offer a route to durable, broad-spectrum resistance against oomycete pathogens without relying on rapidly outmaneuvered resistance genes. The authors note that future work should map the precise hierarchy of this signaling network and determine how spatially separated cell death regulators are coordinated to fine-tune plant immunity.

Subject of Research: ER stress-associated plant immunity and the RTP1-BI-1 regulatory module governing resistance to Phytophthora parasitica in Arabidopsis

Article Title: Bax inhibitor-1 confers resistance to Phytophthora parasitica and is antagonized by RTP1 in Arabidopsis

Article References: Fang, Y., Zhang, J., Gao, X., Guo, S., Xu, X., Wang, B., Zheng, Q., Shan, W., & Qiang, X. (2026). Bax inhibitor-1 confers resistance to Phytophthora parasitica and is antagonized by RTP1 in Arabidopsis. Stress Biology, 6(1), Article 46. https://doi.org/10.1007/s44154-026-00318-0

Image Credits: AI Generated

DOI: 10.1007/s44154-026-00318-0

Keywords: plant immunity, Bax inhibitor-1, RTP1, Phytophthora parasitica, ER stress, unfolded protein response, bZIP60, bZIP28, programmed cell death, susceptibility genes, Arabidopsis, disease resistance

The study’s central engine was summary-data-based Mendelian randomization, or SMR, a statistical technique that exploits naturally occurring genetic variation to probe whether molecular traits influence disease risk. Because genetic variants are randomly allocated at conception, much like coins flipped by nature, they are largely immune to the confounding and reverse causation that plague conventional observational studies. In an SMR analysis, variants that alter, say, the methylation level of a DNA site can be used as instruments to ask whether that methylation change has a downstream causal effect on disease. The method requires that the same variant be associated with both the molecular trait and the outcome, and the strength of the inferred relationship depends on the biology linking the two.

What made this study ambitious was the stacking of three molecular layers on top of a genome-wide association study (GWAS) of major depressive disorder. The researchers merged the MDD GWAS summary statistics with blood-derived cis-methylation quantitative trait loci (mQTLs), cis-expression quantitative trait loci (eQTLs), and cis-protein quantitative trait loci (pQTLs) datasets. Each layer captures a different rung on the ladder from DNA to function: methylation marks influence how genes are regulated, eQTLs reveal how those regulatory differences change gene expression, and pQTLs show how genetic variation alters the abundance of proteins circulating in the blood. By screening candidate signals at every rung, the team could trace a provisional causal chain from epigenetic regulation through gene activity to protein level and finally to disease risk.

The initial screening in the discovery cohort yielded a substantial haul. Eighty-six methylation sites, fifteen genes, and three proteins passed the prespecified SMR thresholds, suggesting that protein folding-related biology was repeatedly intersecting with depression-associated genetic signals. But genomic screening is notoriously prone to false positives, so the investigators applied a false discovery rate (FDR) correction to rein in spurious findings. After this stricter accounting, eleven methylation sites mapping to five genes remained statistically significant at the methylation layer. The expression and protein-level signals, by contrast, did not survive multiple-testing correction and were classified as nominal or suggestive. This hierarchy of evidence is itself informative: it points to methylation, the layer closest to gene regulation, as the tier where protein folding-related genetics and depression risk most clearly converge.

Colocalization analysis provided a second, independent filter. When two traits appear to share a genetic association, there is always a possibility that the signal is actually produced by two different variants sitting near each other on the same chromosome, a phenomenon rooted in linkage disequilibrium. Colocalization methods test whether the two association signals are driven by the same causal variant. In this study, colocalization supported shared genetic signals for ten methylation sites, four expression-associated genes, and two proteins. Of those, four methylation signals, two expression signals, and one protein signal showed strong colocalization evidence, with posterior probabilities exceeding 0.8, a benchmark widely regarded as compelling. Signals that survive both SMR and colocalization are far less likely to be artifacts of chromosomal proximity.

Cross-omic integration then allowed the researchers to stitch the layers together. The analyses provided genetically supported evidence for potential regulatory relationships between FNIP2 methylation-related signals and the gene’s expression, and between PDIA3 expression and its protein abundance. In plain terms, the data suggest a plausible chain of causation in which inherited variation alters chemical tags on the FNIP2 gene, which in turn shifts how actively the gene is expressed; separately, variants affecting PDIA3 expression appear to propagate upward to change the amount of PDIA3 protein detectable in blood. Both molecular traits also showed exploratory associations with MDD risk across their corresponding omic layers, hinting at complete, if provisional, chains from variant to molecule to disorder.

The two prioritized genes are biologically intriguing in their own right. PDIA3 encodes a protein disulfide isomerase resident in the endoplasmic reticulum, where it catalyzes the reshuffling of disulfide bonds that allow newly made proteins to assume their correct three-dimensional shapes. FNIP2 interacts with folliculin and participates in AMP-activated protein kinase (AMPK) signaling, a cellular energy-sensing pathway with documented ties to stress responses. Neither gene is a household name in depression research, which is precisely why a systematic, hypothesis-free approach was needed to surface them. Their emergence from an unbiased screen suggests that depression genetics may be whispering about cellular stress biology that conventional candidate-gene studies have overlooked.

Functional enrichment analyses reinforced that interpretation. Gene Ontology and KEGG pathway analyses of the candidate genes implicated proteostasis-related modules, including endoplasmic reticulum stress, the unfolded protein response, chaperone-mediated folding, protein processing, quality control, and antigen presentation. The unfolded protein response is the cell’s emergency program when misfolded proteins accumulate in the endoplasmic reticulum, and chronic activation of this stress pathway has been observed in animal models of depression, including those using chronic unpredictable mild stress. The enrichment of antigen presentation and major histocompatibility complex-related terms also dovetails with a growing literature connecting immune dysregulation to mood disorders, suggesting that protein folding quality control and inflammation may be intertwined strands of the same biological rope.

The team also sought external support through additional analyses, though these remained exploratory. Replication attempts in the FinnGen depression dataset, cross-disorder checks against bipolar disorder, and surveys of brain-region expression data drawn from the Gene Expression Omnibus provided directionally consistent but not definitive signals. The authors are appropriately measured in their conclusions: the findings are genetically supported and hypothesis-generating, and they explicitly call for independent replication and functional validation before PDIA3 or FNIP2 can be considered established depression genes. Genetic instruments indicate association with disease risk through molecular traits; they do not, by themselves, prove how the genes act in neurons or glia.

Even with those caveats, the study’s design offers a template for the next generation of psychiatric genetics. Rather than asking which single variant raises disease risk, multi-omics Mendelian randomization asks which molecular mechanisms inheritable variation plausibly perturbs, and then interrogates those mechanisms layer by layer. The prioritization of protein folding and proteostasis pathways in major depressive disorder reframes depression not merely as a disorder of neurotransmitters but as a condition in which cellular stress, protein quality control and immune signaling may help set the threshold at which adversity tips into illness. If PDIA3 and FNIP2 hold up under replication and laboratory scrutiny, they could point toward biomarkers measurable in blood and, ultimately, toward therapeutic strategies that shore up the cell’s faltering protein-folding machinery in the most vulnerable patients.

One methodological detail worth noting is how the authors guarded against a known weakness of SMR: horizontal pleiotropy, in which an instrument variant influences the disease through a pathway unrelated to the molecular trait under study. The HEIDI test addresses this by examining whether the association between the instrument and the outcome is consistent across many variants scattered across the locus. A genuine causal effect should show a uniform signal, whereas linkage-driven artifacts tend to concentrate among variants closest to the probe. By requiring HEIDI testing alongside colocalization, the analysis applied two complementary safeguards against the same class of false positive, which strengthens confidence in the methylation-layer findings that survived both filters.

The choice of blood as the tissue source for all three molecular layers also deserves consideration. Blood is far easier to sample than brain tissue, which is why most large-scale QTL reference panels are built from it, and peripheral methylation and protein signals can serve as accessible biomarkers. Yet depression is a disorder of the brain, and regulatory biology in blood does not always mirror that in neural tissue. The exploratory surveys of brain-region expression data, including the anterior cingulate cortex, represent an early attempt to bridge this gap, and the authors themselves flag these analyses as preliminary rather than confirmatory.

The reporting of the study followed STROBE-MR guidelines, a checklist designed to improve transparency in Mendelian randomization research by requiring explicit documentation of instrument selection, sensitivity analyses, and potential pleiotropy. Such standardized reporting matters because genetic instruments can fail in subtle ways, and readers need enough detail to judge whether assumptions hold. The open-access publication also means that the supplementary tables, which contain the full sets of screened methylation sites, genes, and proteins, are available to any laboratory wishing to reanalyze the signals or design follow-up experiments targeting PDIA3 or FNIP2 in cellular models of stress.

Subject of Research: Genetically supported associations between protein folding-related genes and major depressive disorder identified through multi-omics Mendelian randomization.

Article Title: Unraveling the role of protein folding-related genes in depression through multi-omics mendelian randomization

Article References: Wang, J., He, S., Cui, J., & Li, H. (2026). Unraveling the role of protein folding-related genes in depression through multi-omics mendelian randomization. Annals of General Psychiatry. https://doi.org/10.1186/s12991-026-00697-8

Image Credits: AI Generated

DOI: 10.1186/s12991-026-00697-8

Keywords: depression, major depressive disorder, protein folding, Mendelian randomization, multi-omics, PDIA3, FNIP2, DNA methylation, colocalization, unfolded protein response, genetics, psychiatry